Please login to the form below

Not currently logged in
Email:
Password:

Europe pharma stocks take fall

European stocks have fallen today in the wake of drug test failures announced by Actelion and AstraZeneca

European stocks have fallen today in the wake of drug test failures announced by both Actelion and AstraZeneca.

Europe's largest biotech Actelion fell 8 per cent after its haemorrhage drug clazosentan failed in a late-stage study, lessening the chances of it making it to market.

AstraZeneca lost 1.5 per cent after the company's experimental prostate cancer pill zibotentan failed to improve survival in a late-stage clinical trial, dealing a fresh blow to its oncology pipeline.

"We've seen a bit of a pause for breath today and it seems like the market is running out of a bit of steam," said Joshua Raymond, markets strategist at City Index.

27th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics